US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials? - Sorbonne Université
Journal Articles JAMA neurology Year : 2021

US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?

Abstract

No abstract available
Fichier principal
Vignette du fichier
Manuscript_R2_clean.pdf (382.08 Ko) Télécharger le fichier
Fig with arrows.pdf (80.26 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03668175 , version 1 (15-11-2022)

Identifiers

Cite

Vincent Planche, Nicolas Villain. US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?. JAMA neurology, 2021, 78 (11), pp.1307. ⟨10.1001/jamaneurol.2021.3126⟩. ⟨hal-03668175⟩
24 View
301 Download

Altmetric

Share

More